[The effect of carbocromen on cardiac cyclic adenosine-monophosphate].
The coronary-active drug 3-2-diethylaminoethyl)-4-methyl-7-(carbethoxy-methoxy)-2-oxo-1,2-chromene-hydrochloride (carbocromen, Intensain) is known to be an inhibitor of phosphodiesterase (PDE). After intravenous as well as after intraduodenal application of therapeutic doses carbocromen increases in vivo the cAMP-contents of the hearts of rats (by up to 30%) and dogs (up to 50%). This effect is dose related. Correlations between the pharmacokinetic properties and metabolic actions of carbocromen and its influence on the adenylcyclase system are discussed.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002866:Chromonar / Q000008:administration & dosage / Q000494:pharmacology*; D003374:Coumarins / Q000494:pharmacology*; D000242:Cyclic AMP / Q000378:metabolism*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D007275:Injections, Intravenous; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors; D051381:Rats; D013268:Stimulation, Chemical
D003374:Coumarins; D010726:Phosphodiesterase Inhibitors; D000242:Cyclic AMP; D007545:Isoproterenol; D002866:Chromonar
Wirkung von Carbocromen auf cyclisches Adenosinmonophosphat im Herzen